Bot: Removing protection template from an unprotected page

2023-08-31T19:20:03Z

Removing protection template from an unprotected page

← Older revision		Revision as of 00:50, 1 September 2023
Line 1:		Line 1:
	{{Short description\|Group of diseases involving abnormal cell growth and spread}}		{{Short description\|Group of diseases involving abnormal cell growth and spread}}
	{{About\|the group of diseases}}		{{About\|the group of diseases}}
	~~{{Sprotected2}}~~

	{{Use dmy dates\|date=September 2022}}		{{Use dmy dates\|date=September 2022}}
	{{Infobox medical condition (new)		{{Infobox medical condition (new)
Line 226:		Line 224:
	{{Main\|Tumor metabolome}}		{{Main\|Tumor metabolome}}

	Normal cells typically generate only about 30% of energy from [[glycolysis]],<ref name="pmid23226794">{{cite journal \| vauthors = Zheng J \| title=Energy metabolism of cancer: Glycolysis versus oxidative phosphorylation (Review) \| journal=[[Oncology Letters]] \| volume=4 \| issue=6 \| pages=1151–1157 \| year=2012 \| doi = 10.3892/ol.2012.928 \| pmc= 3506713 \| pmid=23226794}}</ref> whereas most cancers rely on glycolysis for energy production ([[Warburg effect (oncology)\|Warburg effect]]).<ref name="pmid20181022">{{cite journal \| vauthors = Seyfried TN, Shelton LM \| title=Cancer as a metabolic disease \| journal=[[Nutrition & Metabolism]] \| volume=7 \| pages=7 \| year=2010 \| doi = 10.1186/1743-7075-7-7 \| pmc= 2845135 \| pmid=20181022 \| doi-access=free }}</ref><ref name="pmid31781842">{{cite journal \| vauthors = Weiss JM \| title=The promise and peril of targeting cell metabolism for cancer therapy \| journal=[[Cancer Immunology, Immunotherapy]] \| volume=69 \| issue=2 \| pages=255–261 \| year=2020 \| doi = 10.1007/s00262-019-02432-7 \| pmc= 7004869 \| pmid=31781842}}</ref><ref name="pmid32523242">{{cite journal \| vauthors = Al-Azzam N \| title=Sirtuin 6 and metabolic genes interplay in Warburg effect in cancers\| journal=[[Journal of Clinical Biochemistry and Nutrition]] \| volume=66 \| issue=3 \| pages=169–175 \| year=2020 \| url=https://www.jbc.org/content/295/32/11021.long \| doi = 10.3164/jcbn.19-110 \| pmc= 7263929 \| pmid=32523242}}</ref> But a minority of cancer types rely on [[oxidative phosphorylation]] as the primary energy source, including [[lymphoma]], [[leukemia]], and [[endometrial cancer]].<ref name="pmid33028168">{{cite journal \| vauthors = Farhadi P, Yarani R, Dokaneheifard S, Mansouri K \| title = The emerging role of targeting cancer metabolism for cancer therapy \| journal = [[Tumor Biology]] \| volume = 42 \| issue = 10 \| pages = 1010428320965284 \| year = 2020 \| doi = 10.1177/1010428320965284 \| pmid = 33028168 \| s2cid = 222214285 \| doi-access = free }}</ref> Even in these cases, however, the use of glycolysis as an energy source rarely exceeds 60%.<ref name="pmid23226794" /> A few cancers use [[glutamine]] as the major energy source, partly because it provides nitrogen required for [[nucleotide]] (DNA, RNA) synthesis.<ref name="pmid26771115">{{cite journal \| vauthors=Pavlova NN, Thompson CB \| title=The Emerging Hallmarks of Cancer Metabolism \| journal=[[Cell Metabolism]] \| volume=23 \| issue=1 \| pages=27–47 \| year=2016 \| doi = 10.1016/j.cmet.2015.12.006 \| pmc= 4715268 \| pmid=26771115}}</ref~~><ref name="pmid23226794" /~~> [[Cancer stem cell]]s often use oxidative phosphorylation or glutamine as a primary energy source.<ref name="pmid32670883">{{cite journal \| vauthors=Yadav UP, Singh T, Kumar P, Mehta K \| title=Metabolic Adaptations in Cancer Stem Cells \| journal=[[Frontiers in Oncology]] \| volume=10 \| pages=1010 \| year=2020 \| doi = 10.3389/fonc.2020.01010 \| pmc= 7330710 \| pmid=32670883\| doi-access=free }}</ref>		Normal cells typically generate only about 30% of energy from [[glycolysis]],<ref name="pmid23226794">{{cite journal \| vauthors = Zheng J \| title=Energy metabolism of cancer: Glycolysis versus oxidative phosphorylation (Review) \| journal=[[Oncology Letters]] \| volume=4 \| issue=6 \| pages=1151–1157 \| year=2012 \| doi = 10.3892/ol.2012.928 \| pmc= 3506713 \| pmid=23226794}}</ref> whereas most cancers rely on glycolysis for energy production ([[Warburg effect (oncology)\|Warburg effect]]).<ref name="pmid20181022">{{cite journal \| vauthors = Seyfried TN, Shelton LM \| title=Cancer as a metabolic disease \| journal=[[Nutrition & Metabolism]] \| volume=7 \| pages=7 \| year=2010 \| doi = 10.1186/1743-7075-7-7 \| pmc= 2845135 \| pmid=20181022 \| doi-access=free }}</ref><ref name="pmid31781842">{{cite journal \| vauthors = Weiss JM \| title=The promise and peril of targeting cell metabolism for cancer therapy \| journal=[[Cancer Immunology, Immunotherapy]] \| volume=69 \| issue=2 \| pages=255–261 \| year=2020 \| doi = 10.1007/s00262-019-02432-7 \| pmc= 7004869 \| pmid=31781842}}</ref><ref name="pmid32523242">{{cite journal \| vauthors = Al-Azzam N \| title=Sirtuin 6 and metabolic genes interplay in Warburg effect in cancers\| journal=[[Journal of Clinical Biochemistry and Nutrition]] \| volume=66 \| issue=3 \| pages=169–175 \| year=2020 \| url=https://www.jbc.org/content/295/32/11021.long \| doi = 10.3164/jcbn.19-110 \| pmc= 7263929 \| pmid=32523242}}</ref> But a minority of cancer types rely on [[oxidative phosphorylation]] as the primary energy source, including [[lymphoma]], [[leukemia]], and [[endometrial cancer]].<ref name="pmid33028168">{{cite journal \| vauthors = Farhadi P, Yarani R, Dokaneheifard S, Mansouri K \| title = The emerging role of targeting cancer metabolism for cancer therapy \| journal = [[Tumor Biology]] \| volume = 42 \| issue = 10 \| pages = 1010428320965284 \| year = 2020 \| doi = 10.1177/1010428320965284 \| pmid = 33028168 \| s2cid = 222214285 \| doi-access = free }}</ref> Even in these cases, however, the use of glycolysis as an energy source rarely exceeds 60%.<ref name="pmid23226794" /> A few cancers use [[glutamine]] as the major energy source, partly because it provides nitrogen required for [[nucleotide]] (DNA, RNA) synthesis.<ref name="pmid23226794" /><ref name="pmid26771115">{{cite journal \| vauthors=Pavlova NN, Thompson CB \| title=The Emerging Hallmarks of Cancer Metabolism \| journal=[[Cell Metabolism]] \| volume=23 \| issue=1 \| pages=27–47 \| year=2016 \| doi = 10.1016/j.cmet.2015.12.006 \| pmc= 4715268 \| pmid=26771115}}</ref> [[Cancer stem cell]]s often use oxidative phosphorylation or glutamine as a primary energy source.<ref name="pmid32670883">{{cite journal \| vauthors=Yadav UP, Singh T, Kumar P, Mehta K \| title=Metabolic Adaptations in Cancer Stem Cells \| journal=[[Frontiers in Oncology]] \| volume=10 \| pages=1010 \| year=2020 \| doi = 10.3389/fonc.2020.01010 \| pmc= 7330710 \| pmid=32670883\| doi-access=free }}</ref>

	Several studies have indicated that the enzyme [[sirtuin 6]] is selectively inactivated during [[oncogenesis]] in a variety of tumor types by inducing glycolysis.<ref name="pmid32523242" /> Another [[sirtuin]], [[sirtuin 3]] inhibits cancers that depend upon [[glycolysis]], but promotes cancers that depend upon [[oxidative phosphorylation]].<ref name="pmid32724473">{{cite journal \| vauthors=Zhang J, Xiang H, Rong-Rong He R, Liu B \| title=Mitochondrial Sirtuin 3: New emerging biological function and therapeutic target \| journal=[[Theranostics (journal)\|Theranostics]] \| volume=10 \| issue=18 \| pages=8315–8342\| year=2020 \| doi = 10.7150/thno.45922 \| pmc=7381741 \| pmid=32724473}}</ref>		Several studies have indicated that the enzyme [[sirtuin 6]] is selectively inactivated during [[oncogenesis]] in a variety of tumor types by inducing glycolysis.<ref name="pmid32523242" /> Another [[sirtuin]], [[sirtuin 3]] inhibits cancers that depend upon [[glycolysis]], but promotes cancers that depend upon [[oxidative phosphorylation]].<ref name="pmid32724473">{{cite journal \| vauthors=Zhang J, Xiang H, Rong-Rong He R, Liu B \| title=Mitochondrial Sirtuin 3: New emerging biological function and therapeutic target \| journal=[[Theranostics (journal)\|Theranostics]] \| volume=10 \| issue=18 \| pages=8315–8342\| year=2020 \| doi = 10.7150/thno.45922 \| pmc=7381741 \| pmid=32724473}}</ref>
Line 444:		Line 442:

	=== Economic effect ===		=== Economic effect ===
	The total health care expenditure on cancer in the US was estimated to be $80.2 billion in 2015.<ref>{{cite web \|title=Economic Impact of Cancer \|url=https://www.cancer.org/cancer/cancer-basics/economic-impact-of-cancer.html \|website=American Cancer Society \|date=3 January 2018 \|access-date=5 July 2018}}</ref> Even though cancer-related health care expenditure have increased in absolute terms during recent decades, the share of health expenditure devoted to cancer treatment has remained close to 5% between the 1960s and 2004.<ref>{{cite journal \|vauthors=Bosanquet N, Sikora K \|title=The economics of cancer care in the UK \|journal=Lancet Oncology \|volume=5 \|issue=9 \|pages=568–74 \|year=2004 \|pmid=15337487 \|doi=10.1016/S1470-2045(04)01569-4}}</ref><ref>{{cite journal \|vauthors=Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML \|title=Projections of the cost of cancer care in the United States: 2010–2020 \|journal=Journal of the National Cancer Institute \|volume=103 \|issue=2 \|pages=117–28 \|year=2011 \|pmid=21228314 \|pmc=3107566 \|doi=10.1093/jnci/djq495}}</ref> A similar pattern has been observed in Europe where about 6% of all health care expenditure are spent on cancer treatment.<ref>{{cite journal \|vauthors=Jönsson B, Hofmarcher T, Lindgren P, Wilking N \|title=The cost and burden of cancer in the European Union 1995–2014 \|journal=European Journal of Cancer \|volume=66 \|issue=Oct \|pages=162–70 \|year=2016 \|pmid=27589247 \|doi=10.1016/j.ejca.2016.06.022}}</ref><ref name=EJC2018>{{cite journal \|vauthors=Hofmarcher T, Lindgren P, Wilking N, Jönsson B \|title=The cost of cancer in Europe 2018 \|journal=European Journal of Cancer \|volume=129 \|issue=Apr \|pages=41–49 \|year=2020 \|pmid=32120274 \|doi=10.1016/j.ejca.2020.01.011\|doi-access=free }}</ref> In addition to health care expenditure and [[financial toxicity]], cancer causes indirect costs in the form of productivity losses due to sick days, permanent incapacity and disability as well as premature death during working age. Cancer causes also costs for informal care. Indirect costs and informal care costs are typically estimated to exceed or equal the health care costs of cancer.<ref>{{cite journal \|vauthors=Luengo-Fernandez R, Leal J, Gray A, Sullivan R \|title=Economic burden of cancer across the European Union: a population-based cost analysis \|journal=Lancet Oncology \|volume=14 \|issue=12 \|pages=1165–74 \|year=2013 \|pmid=24131614 \|doi=10.1016/S1470-2045(13)70442-X}}</ref~~><ref name=EJC2018 /~~>		The total health care expenditure on cancer in the US was estimated to be $80.2 billion in 2015.<ref>{{cite web \|title=Economic Impact of Cancer \|url=https://www.cancer.org/cancer/cancer-basics/economic-impact-of-cancer.html \|website=American Cancer Society \|date=3 January 2018 \|access-date=5 July 2018}}</ref> Even though cancer-related health care expenditure have increased in absolute terms during recent decades, the share of health expenditure devoted to cancer treatment has remained close to 5% between the 1960s and 2004.<ref>{{cite journal \|vauthors=Bosanquet N, Sikora K \|title=The economics of cancer care in the UK \|journal=Lancet Oncology \|volume=5 \|issue=9 \|pages=568–74 \|year=2004 \|pmid=15337487 \|doi=10.1016/S1470-2045(04)01569-4}}</ref><ref>{{cite journal \|vauthors=Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML \|title=Projections of the cost of cancer care in the United States: 2010–2020 \|journal=Journal of the National Cancer Institute \|volume=103 \|issue=2 \|pages=117–28 \|year=2011 \|pmid=21228314 \|pmc=3107566 \|doi=10.1093/jnci/djq495}}</ref> A similar pattern has been observed in Europe where about 6% of all health care expenditure are spent on cancer treatment.<ref>{{cite journal \|vauthors=Jönsson B, Hofmarcher T, Lindgren P, Wilking N \|title=The cost and burden of cancer in the European Union 1995–2014 \|journal=European Journal of Cancer \|volume=66 \|issue=Oct \|pages=162–70 \|year=2016 \|pmid=27589247 \|doi=10.1016/j.ejca.2016.06.022}}</ref><ref name=EJC2018>{{cite journal \|vauthors=Hofmarcher T, Lindgren P, Wilking N, Jönsson B \|title=The cost of cancer in Europe 2018 \|journal=European Journal of Cancer \|volume=129 \|issue=Apr \|pages=41–49 \|year=2020 \|pmid=32120274 \|doi=10.1016/j.ejca.2020.01.011\|doi-access=free }}</ref> In addition to health care expenditure and [[financial toxicity]], cancer causes indirect costs in the form of productivity losses due to sick days, permanent incapacity and disability as well as premature death during working age. Cancer causes also costs for informal care. Indirect costs and informal care costs are typically estimated to exceed or equal the health care costs of cancer.<ref name=EJC2018 /><ref>{{cite journal \|vauthors=Luengo-Fernandez R, Leal J, Gray A, Sullivan R \|title=Economic burden of cancer across the European Union: a population-based cost analysis \|journal=Lancet Oncology \|volume=14 \|issue=12 \|pages=1165–74 \|year=2013 \|pmid=24131614 \|doi=10.1016/S1470-2045(13)70442-X}}</ref>

	=== Workplace ===		=== Workplace ===
Line 504:		Line 502:

	== External links ==		== External links ==
	~~{{wikiversity\|Cell biology/Cancer}}~~
	~~{{EB1911 poster\|Cancer}}~~
	~~{{Commons category\|Cancers}}~~
	* {{curlie\|Health/Conditions_and_Diseases/Cancer/}}		* {{curlie\|Health/Conditions_and_Diseases/Cancer/}}
	* [https://www.theatlantic.com/health/archive/2021/08/caitlin-flanagan-secret-of-surviving-cancer/619844/ "On telling cancer patients to have a positive attitude"] at ''[[The Atlantic]]''		* [https://www.theatlantic.com/health/archive/2021/08/caitlin-flanagan-secret-of-surviving-cancer/619844/ "On telling cancer patients to have a positive attitude"] at ''[[The Atlantic]]''

	~~{{Medical condition classification and resources~~
	~~\| DiseasesDB = 28843~~
	~~\| ICD10 ={{ICD10\|C00-C97}}~~
	~~\| ICD9 = {{ICD9\|140}}—{{ICD9\|239}}~~
	~~\| ICDO =~~
	~~\| MedlinePlus = 001289~~
	~~\| eMedicineSubj =~~
	~~\| eMedicineTopic =~~
	~~\| MeshID = D009369~~
	}}
	~~{{Tumors\|state=uncollapsed}}~~
	~~{{Disease groups}}~~
	~~{{Authority control}}~~

	[[Category:Cancer\| ]]		[[Category:Cancer\| ]]

Bot: Removing protection template from an unprotected page

2023-08-30T05:33:11Z

Removing protection template from an unprotected page

← Older revision		Revision as of 11:03, 30 August 2023
Line 2:		Line 2:
	{{About\|the group of diseases}}		{{About\|the group of diseases}}
	{{Sprotected2}}		{{Sprotected2}}
	~~{{Pp-move-indef}}~~
	{{Use dmy dates\|date=September 2022}}		{{Use dmy dates\|date=September 2022}}
	{{Infobox medical condition (new)		{{Infobox medical condition (new)

Ajay Kumar: Created a new article

2023-08-29T21:04:21Z

Created a new article

Show changes

← Older revision		Revision as of 00:50, 1 September 2023
Line 1:		Line 1:
	{{Short description\|Group of diseases involving abnormal cell growth and spread}}		{{Short description\|Group of diseases involving abnormal cell growth and spread}}
	{{About\|the group of diseases}}		{{About\|the group of diseases}}
	~~{{Sprotected2}}~~

	{{Use dmy dates\|date=September 2022}}		{{Use dmy dates\|date=September 2022}}
	{{Infobox medical condition (new)		{{Infobox medical condition (new)
Line 226:		Line 224:
	{{Main\|Tumor metabolome}}		{{Main\|Tumor metabolome}}

	Normal cells typically generate only about 30% of energy from [[glycolysis]],<ref name="pmid23226794">{{cite journal \| vauthors = Zheng J \| title=Energy metabolism of cancer: Glycolysis versus oxidative phosphorylation (Review) \| journal=[[Oncology Letters]] \| volume=4 \| issue=6 \| pages=1151–1157 \| year=2012 \| doi = 10.3892/ol.2012.928 \| pmc= 3506713 \| pmid=23226794}}</ref> whereas most cancers rely on glycolysis for energy production ([[Warburg effect (oncology)\|Warburg effect]]).<ref name="pmid20181022">{{cite journal \| vauthors = Seyfried TN, Shelton LM \| title=Cancer as a metabolic disease \| journal=[[Nutrition & Metabolism]] \| volume=7 \| pages=7 \| year=2010 \| doi = 10.1186/1743-7075-7-7 \| pmc= 2845135 \| pmid=20181022 \| doi-access=free }}</ref><ref name="pmid31781842">{{cite journal \| vauthors = Weiss JM \| title=The promise and peril of targeting cell metabolism for cancer therapy \| journal=[[Cancer Immunology, Immunotherapy]] \| volume=69 \| issue=2 \| pages=255–261 \| year=2020 \| doi = 10.1007/s00262-019-02432-7 \| pmc= 7004869 \| pmid=31781842}}</ref><ref name="pmid32523242">{{cite journal \| vauthors = Al-Azzam N \| title=Sirtuin 6 and metabolic genes interplay in Warburg effect in cancers\| journal=[[Journal of Clinical Biochemistry and Nutrition]] \| volume=66 \| issue=3 \| pages=169–175 \| year=2020 \| url=https://www.jbc.org/content/295/32/11021.long \| doi = 10.3164/jcbn.19-110 \| pmc= 7263929 \| pmid=32523242}}</ref> But a minority of cancer types rely on [[oxidative phosphorylation]] as the primary energy source, including [[lymphoma]], [[leukemia]], and [[endometrial cancer]].<ref name="pmid33028168">{{cite journal \| vauthors = Farhadi P, Yarani R, Dokaneheifard S, Mansouri K \| title = The emerging role of targeting cancer metabolism for cancer therapy \| journal = [[Tumor Biology]] \| volume = 42 \| issue = 10 \| pages = 1010428320965284 \| year = 2020 \| doi = 10.1177/1010428320965284 \| pmid = 33028168 \| s2cid = 222214285 \| doi-access = free }}</ref> Even in these cases, however, the use of glycolysis as an energy source rarely exceeds 60%.<ref name="pmid23226794" /> A few cancers use [[glutamine]] as the major energy source, partly because it provides nitrogen required for [[nucleotide]] (DNA, RNA) synthesis.<ref name="pmid26771115">{{cite journal \| vauthors=Pavlova NN, Thompson CB \| title=The Emerging Hallmarks of Cancer Metabolism \| journal=[[Cell Metabolism]] \| volume=23 \| issue=1 \| pages=27–47 \| year=2016 \| doi = 10.1016/j.cmet.2015.12.006 \| pmc= 4715268 \| pmid=26771115}}</ref~~><ref name="pmid23226794" /~~> [[Cancer stem cell]]s often use oxidative phosphorylation or glutamine as a primary energy source.<ref name="pmid32670883">{{cite journal \| vauthors=Yadav UP, Singh T, Kumar P, Mehta K \| title=Metabolic Adaptations in Cancer Stem Cells \| journal=[[Frontiers in Oncology]] \| volume=10 \| pages=1010 \| year=2020 \| doi = 10.3389/fonc.2020.01010 \| pmc= 7330710 \| pmid=32670883\| doi-access=free }}</ref>		Normal cells typically generate only about 30% of energy from [[glycolysis]],<ref name="pmid23226794">{{cite journal \| vauthors = Zheng J \| title=Energy metabolism of cancer: Glycolysis versus oxidative phosphorylation (Review) \| journal=[[Oncology Letters]] \| volume=4 \| issue=6 \| pages=1151–1157 \| year=2012 \| doi = 10.3892/ol.2012.928 \| pmc= 3506713 \| pmid=23226794}}</ref> whereas most cancers rely on glycolysis for energy production ([[Warburg effect (oncology)\|Warburg effect]]).<ref name="pmid20181022">{{cite journal \| vauthors = Seyfried TN, Shelton LM \| title=Cancer as a metabolic disease \| journal=[[Nutrition & Metabolism]] \| volume=7 \| pages=7 \| year=2010 \| doi = 10.1186/1743-7075-7-7 \| pmc= 2845135 \| pmid=20181022 \| doi-access=free }}</ref><ref name="pmid31781842">{{cite journal \| vauthors = Weiss JM \| title=The promise and peril of targeting cell metabolism for cancer therapy \| journal=[[Cancer Immunology, Immunotherapy]] \| volume=69 \| issue=2 \| pages=255–261 \| year=2020 \| doi = 10.1007/s00262-019-02432-7 \| pmc= 7004869 \| pmid=31781842}}</ref><ref name="pmid32523242">{{cite journal \| vauthors = Al-Azzam N \| title=Sirtuin 6 and metabolic genes interplay in Warburg effect in cancers\| journal=[[Journal of Clinical Biochemistry and Nutrition]] \| volume=66 \| issue=3 \| pages=169–175 \| year=2020 \| url=https://www.jbc.org/content/295/32/11021.long \| doi = 10.3164/jcbn.19-110 \| pmc= 7263929 \| pmid=32523242}}</ref> But a minority of cancer types rely on [[oxidative phosphorylation]] as the primary energy source, including [[lymphoma]], [[leukemia]], and [[endometrial cancer]].<ref name="pmid33028168">{{cite journal \| vauthors = Farhadi P, Yarani R, Dokaneheifard S, Mansouri K \| title = The emerging role of targeting cancer metabolism for cancer therapy \| journal = [[Tumor Biology]] \| volume = 42 \| issue = 10 \| pages = 1010428320965284 \| year = 2020 \| doi = 10.1177/1010428320965284 \| pmid = 33028168 \| s2cid = 222214285 \| doi-access = free }}</ref> Even in these cases, however, the use of glycolysis as an energy source rarely exceeds 60%.<ref name="pmid23226794" /> A few cancers use [[glutamine]] as the major energy source, partly because it provides nitrogen required for [[nucleotide]] (DNA, RNA) synthesis.<ref name="pmid23226794" /><ref name="pmid26771115">{{cite journal \| vauthors=Pavlova NN, Thompson CB \| title=The Emerging Hallmarks of Cancer Metabolism \| journal=[[Cell Metabolism]] \| volume=23 \| issue=1 \| pages=27–47 \| year=2016 \| doi = 10.1016/j.cmet.2015.12.006 \| pmc= 4715268 \| pmid=26771115}}</ref> [[Cancer stem cell]]s often use oxidative phosphorylation or glutamine as a primary energy source.<ref name="pmid32670883">{{cite journal \| vauthors=Yadav UP, Singh T, Kumar P, Mehta K \| title=Metabolic Adaptations in Cancer Stem Cells \| journal=[[Frontiers in Oncology]] \| volume=10 \| pages=1010 \| year=2020 \| doi = 10.3389/fonc.2020.01010 \| pmc= 7330710 \| pmid=32670883\| doi-access=free }}</ref>

	Several studies have indicated that the enzyme [[sirtuin 6]] is selectively inactivated during [[oncogenesis]] in a variety of tumor types by inducing glycolysis.<ref name="pmid32523242" /> Another [[sirtuin]], [[sirtuin 3]] inhibits cancers that depend upon [[glycolysis]], but promotes cancers that depend upon [[oxidative phosphorylation]].<ref name="pmid32724473">{{cite journal \| vauthors=Zhang J, Xiang H, Rong-Rong He R, Liu B \| title=Mitochondrial Sirtuin 3: New emerging biological function and therapeutic target \| journal=[[Theranostics (journal)\|Theranostics]] \| volume=10 \| issue=18 \| pages=8315–8342\| year=2020 \| doi = 10.7150/thno.45922 \| pmc=7381741 \| pmid=32724473}}</ref>		Several studies have indicated that the enzyme [[sirtuin 6]] is selectively inactivated during [[oncogenesis]] in a variety of tumor types by inducing glycolysis.<ref name="pmid32523242" /> Another [[sirtuin]], [[sirtuin 3]] inhibits cancers that depend upon [[glycolysis]], but promotes cancers that depend upon [[oxidative phosphorylation]].<ref name="pmid32724473">{{cite journal \| vauthors=Zhang J, Xiang H, Rong-Rong He R, Liu B \| title=Mitochondrial Sirtuin 3: New emerging biological function and therapeutic target \| journal=[[Theranostics (journal)\|Theranostics]] \| volume=10 \| issue=18 \| pages=8315–8342\| year=2020 \| doi = 10.7150/thno.45922 \| pmc=7381741 \| pmid=32724473}}</ref>
Line 444:		Line 442:

	=== Economic effect ===		=== Economic effect ===
	The total health care expenditure on cancer in the US was estimated to be $80.2 billion in 2015.<ref>{{cite web \|title=Economic Impact of Cancer \|url=https://www.cancer.org/cancer/cancer-basics/economic-impact-of-cancer.html \|website=American Cancer Society \|date=3 January 2018 \|access-date=5 July 2018}}</ref> Even though cancer-related health care expenditure have increased in absolute terms during recent decades, the share of health expenditure devoted to cancer treatment has remained close to 5% between the 1960s and 2004.<ref>{{cite journal \|vauthors=Bosanquet N, Sikora K \|title=The economics of cancer care in the UK \|journal=Lancet Oncology \|volume=5 \|issue=9 \|pages=568–74 \|year=2004 \|pmid=15337487 \|doi=10.1016/S1470-2045(04)01569-4}}</ref><ref>{{cite journal \|vauthors=Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML \|title=Projections of the cost of cancer care in the United States: 2010–2020 \|journal=Journal of the National Cancer Institute \|volume=103 \|issue=2 \|pages=117–28 \|year=2011 \|pmid=21228314 \|pmc=3107566 \|doi=10.1093/jnci/djq495}}</ref> A similar pattern has been observed in Europe where about 6% of all health care expenditure are spent on cancer treatment.<ref>{{cite journal \|vauthors=Jönsson B, Hofmarcher T, Lindgren P, Wilking N \|title=The cost and burden of cancer in the European Union 1995–2014 \|journal=European Journal of Cancer \|volume=66 \|issue=Oct \|pages=162–70 \|year=2016 \|pmid=27589247 \|doi=10.1016/j.ejca.2016.06.022}}</ref><ref name=EJC2018>{{cite journal \|vauthors=Hofmarcher T, Lindgren P, Wilking N, Jönsson B \|title=The cost of cancer in Europe 2018 \|journal=European Journal of Cancer \|volume=129 \|issue=Apr \|pages=41–49 \|year=2020 \|pmid=32120274 \|doi=10.1016/j.ejca.2020.01.011\|doi-access=free }}</ref> In addition to health care expenditure and [[financial toxicity]], cancer causes indirect costs in the form of productivity losses due to sick days, permanent incapacity and disability as well as premature death during working age. Cancer causes also costs for informal care. Indirect costs and informal care costs are typically estimated to exceed or equal the health care costs of cancer.<ref>{{cite journal \|vauthors=Luengo-Fernandez R, Leal J, Gray A, Sullivan R \|title=Economic burden of cancer across the European Union: a population-based cost analysis \|journal=Lancet Oncology \|volume=14 \|issue=12 \|pages=1165–74 \|year=2013 \|pmid=24131614 \|doi=10.1016/S1470-2045(13)70442-X}}</ref~~><ref name=EJC2018 /~~>		The total health care expenditure on cancer in the US was estimated to be $80.2 billion in 2015.<ref>{{cite web \|title=Economic Impact of Cancer \|url=https://www.cancer.org/cancer/cancer-basics/economic-impact-of-cancer.html \|website=American Cancer Society \|date=3 January 2018 \|access-date=5 July 2018}}</ref> Even though cancer-related health care expenditure have increased in absolute terms during recent decades, the share of health expenditure devoted to cancer treatment has remained close to 5% between the 1960s and 2004.<ref>{{cite journal \|vauthors=Bosanquet N, Sikora K \|title=The economics of cancer care in the UK \|journal=Lancet Oncology \|volume=5 \|issue=9 \|pages=568–74 \|year=2004 \|pmid=15337487 \|doi=10.1016/S1470-2045(04)01569-4}}</ref><ref>{{cite journal \|vauthors=Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML \|title=Projections of the cost of cancer care in the United States: 2010–2020 \|journal=Journal of the National Cancer Institute \|volume=103 \|issue=2 \|pages=117–28 \|year=2011 \|pmid=21228314 \|pmc=3107566 \|doi=10.1093/jnci/djq495}}</ref> A similar pattern has been observed in Europe where about 6% of all health care expenditure are spent on cancer treatment.<ref>{{cite journal \|vauthors=Jönsson B, Hofmarcher T, Lindgren P, Wilking N \|title=The cost and burden of cancer in the European Union 1995–2014 \|journal=European Journal of Cancer \|volume=66 \|issue=Oct \|pages=162–70 \|year=2016 \|pmid=27589247 \|doi=10.1016/j.ejca.2016.06.022}}</ref><ref name=EJC2018>{{cite journal \|vauthors=Hofmarcher T, Lindgren P, Wilking N, Jönsson B \|title=The cost of cancer in Europe 2018 \|journal=European Journal of Cancer \|volume=129 \|issue=Apr \|pages=41–49 \|year=2020 \|pmid=32120274 \|doi=10.1016/j.ejca.2020.01.011\|doi-access=free }}</ref> In addition to health care expenditure and [[financial toxicity]], cancer causes indirect costs in the form of productivity losses due to sick days, permanent incapacity and disability as well as premature death during working age. Cancer causes also costs for informal care. Indirect costs and informal care costs are typically estimated to exceed or equal the health care costs of cancer.<ref name=EJC2018 /><ref>{{cite journal \|vauthors=Luengo-Fernandez R, Leal J, Gray A, Sullivan R \|title=Economic burden of cancer across the European Union: a population-based cost analysis \|journal=Lancet Oncology \|volume=14 \|issue=12 \|pages=1165–74 \|year=2013 \|pmid=24131614 \|doi=10.1016/S1470-2045(13)70442-X}}</ref>

	=== Workplace ===		=== Workplace ===
Line 504:		Line 502:

	== External links ==		== External links ==
	~~{{wikiversity\|Cell biology/Cancer}}~~
	~~{{EB1911 poster\|Cancer}}~~
	~~{{Commons category\|Cancers}}~~
	* {{curlie\|Health/Conditions_and_Diseases/Cancer/}}		* {{curlie\|Health/Conditions_and_Diseases/Cancer/}}
	* [https://www.theatlantic.com/health/archive/2021/08/caitlin-flanagan-secret-of-surviving-cancer/619844/ "On telling cancer patients to have a positive attitude"] at ''[[The Atlantic]]''		* [https://www.theatlantic.com/health/archive/2021/08/caitlin-flanagan-secret-of-surviving-cancer/619844/ "On telling cancer patients to have a positive attitude"] at ''[[The Atlantic]]''

	~~{{Medical condition classification and resources~~
	~~\| DiseasesDB = 28843~~
	~~\| ICD10 ={{ICD10\|C00-C97}}~~
	~~\| ICD9 = {{ICD9\|140}}—{{ICD9\|239}}~~
	~~\| ICDO =~~
	~~\| MedlinePlus = 001289~~
	~~\| eMedicineSubj =~~
	~~\| eMedicineTopic =~~
	~~\| MeshID = D009369~~
	}}
	~~{{Tumors\|state=uncollapsed}}~~
	~~{{Disease groups}}~~
	~~{{Authority control}}~~

	[[Category:Cancer\| ]]		[[Category:Cancer\| ]]

Cancer - Revision history

Bot: Removing protection template from an unprotected page

Bot: Removing protection template from an unprotected page

Ajay Kumar: Created a new article